Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 61-71

  Moibi, Jacob A ^a   Mak, Allan L ^a   Sun, Bo ^a   Moore, Ronald B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bladder cancer; Gemcitabine; Intravesical chemotherapy; TRAIL

Indexed keywords

CASPASE; GEMCITABINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PENETRATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CASPASES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS;

EID: 79956016364     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1023     Document Type: Article

References (54)

1. Gontero P, Marini L and Frea B: Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. Br J Urol 96: 970-976, 2005 (Pubitemid 41531397)
2. Ludwig AT, Moore JM, Luo Y, et al: Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin- induced antitumor activity. Cancer Res 64: 3386-3390, 2004 (Pubitemid 38657909)
3. Simons M, Nauseef W and Griffith T: Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer. Immunol Res 39: 79-93, 2007 (Pubitemid 47574899)
4. McKnight JJ, Gray SB, O'Kane HF, Johnston SR and Williamson KE: Apoptosis and chemotherapy for bladder cancer. J Urol 173: 683-690, 2005
5. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 326: 1-16, 1997.
6. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
7. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997 (Pubitemid 27366733)
8. Tibbetts MD, Zheng L and Lenardo MJ: The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 4: 404-409, 2003. (Pubitemid 36592429)
9. Jin X, Wu X-X, Abdel-Muneem Nouh MA and Kakehi Y: Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 177: 1894-1899, 2007.
10. Shankar S, Singh TR and Srivastava RK: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61: 35-49, 2004 (Pubitemid 39095693)
11. O'Kane HF, Watson CJ, Johnston SR, et al: Targeting death receptors in bladder, prostate and renal cancer. J Urol 175: 432-438, 2006. (Pubitemid 43067319)
12. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-Difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990. (Pubitemid 20225688)
13. Stadler W, Kuzel T, Roth B, Raghavan D and Dorr F: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398, 1997 (Pubitemid 27485860)
14. Moore M, Winquist E, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881, 1999 (Pubitemid 29415247)
15. Kilani RT, Tamimi Y, Karmali S, et al: Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 13: 557-566, 2002. (Pubitemid 34816450)
16. Sun B, Moibi JA, Mak A, Xiao Z, Roa W and Moore RB: Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. J Urol 181: 1361-1371, 2009.
17. Kilani RT, Tamimi Y, Hanel EG, et al: Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res 93: 1-12, 2003. (Pubitemid 36513881)
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
19. Xu ZW, Kleeff J, Friess H, Buchler MW and Solioz M: Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23: 251-258, 2003. (Pubitemid 36358526)
20. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
21. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S: Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer 79: 1651-1656, 1999 (Pubitemid 29132285)
22. Ye D, Li H, Qian S, Sun Y, Zheng J and Ma Y: Bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 160: 2025-2029, 1998. (Pubitemid 128703606)
23. Duggan BJ, Maxwell P, Kelly JD, et al: The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 166: 1098-1105, 2001. (Pubitemid 32751052)
24. Danik M, Chabot JG, Mercier C, et al: Human gliomas and epileptic foci express high levels of an mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci USA 88: 8577-8581, 1991. (Pubitemid 21915400)
25. Sensibar JA, Sutkowski DM, Raffo A, et al: Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (Clusterin). Cancer Res 55: 2431-2437, 1995
26. Miyake H, Nelson C, Rennie PS and Gleave ME: Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60: 2547-2554, 2000. (Pubitemid 30262451)
27. Xu ZW, Kleeff J, Friess H, Buchler MW and Solioz M: Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23: 251-258, 2003. (Pubitemid 36358526)
28. Steele LP, Georgopoulos NT, Southgate J, Selby PJ and Trejdosiewicz LK: Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 13: 1564-1576, 2006. (Pubitemid 44210359)
29. Mom CH, Verweij J, Oldenhuis CNAM, et al: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15: 5584-5590, 2009.
30. Arts HJG, de Jong S, Hollema H, ten Hoor K, van der Zee AGJ and de Vries EGE: Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92: 794-800, 2004 (Pubitemid 38251379)
31. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA and Bonavida B: Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6: 1387-1399, 2007 (Pubitemid 46712002)
32. Seol JW, Chaudhari AA, Lee YJ, et al: Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep 18: 523-529, 2007
33. Bold RJ, Chandra J and McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279-285, 1999 (Pubitemid 29221014)
34. Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B and Miki T: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 165: 263-270, 2001.
35. Lin T, Zhang L, Davis J, et al: Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 8: 441-448, 2003. (Pubitemid 37161466)
36. Chou T, Motzer R, Tong Y and Bosl G: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994 (Pubitemid 24330215)
37. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999 (Pubitemid 30035640)
38. Witjes JA, Vriesema JLJ, van der Heijden AG, Peters GJ and Schalken JA: Pharmacokinetics of intravesical gemcitabine: A preclinical study in pigs. Eur Urol 44: 615-619, 2003. (Pubitemid 37328641)
39. Laufer M, Ramalingam S, Schoenberg MP, et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase I and pharmacokinetic study. J Clin Oncol 21: 697-703, 2003. (Pubitemid 46621905)
40. Dalbagni G, Russo P, Sheinfeld J, et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20: 3193-3198, 2002. (Pubitemid 34831514)
41. De Berardinis E, Antonini G, Peters GJ, et al: Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. Br J Urol 93: 491-494, 2004
42. Palou J, Carcas A, Segarra J, et al: Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 172: 485-488, 2004 (Pubitemid 38900184)
43. Hanel EG, Xiao Z, Wong KK, Lee PWK, Britten RA and Moore RB: A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy. J Urol 172: 2018-2022, 2004 (Pubitemid 39363120)
44. Marini P, Denzinger S, Schiller D, et al: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154, 2006. (Pubitemid 44285983)
45. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000.
46. Younes A and Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526-3534, 2003. (Pubitemid 46594087)
47. Ishimura N, Isomoto H, Bronk SF and Gores GJ: Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290: G129-G136, 2006.
48. Rokhlin OW, Glover RA, Taghiyev AF, et al: Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem 277: 33213-33219, 2002. (Pubitemid 34984840)
49. Muzio M, Chinnaiyan AM, Kischkel FC, et al: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827, 1996. (Pubitemid 26193033)
50. Boldin MP, Goncharov TM, Goltseve YV and Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815, 1996.
51. Kischkel FC, Hellbardt S, Behrmann IGM, Pawlita MKP and Me P: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588, 1995
52. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS and Dixit VM: An induced proximity model for caspase-8 activation. J Biol Chem 273: 2926-2930, 1998. (Pubitemid 28133943)
53. Hao C, Beguinot F, Condorelli G, et al: Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61: 1162-1170, 2001. (Pubitemid 32174439)
54. Ohtsuki T, Kikuchi H, Kowithayakorn T, Sakai T and Ishibashi M: Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. Bioorg Med Chem 17: 6748-6754, 2009